Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.

Objectives Sophisticated scientific methods have facilitated dose individualisation with substantial advancements in therapeutic drug monitoring (TDM) practice. It is unclear whether these methods have translated to the clinical setting. This study aimed to determine current TDM practice for tobramy...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Hospital Pharmacy Vol. 31; no. 4; pp. 301 - 310
Autores principales: Larcombe, Rebecca, Coulthard, Kingsley, Eaton, Vaughn, Tai, Andrew, Reuter, Stephanie, Ward, Michael
Formato: questionnaire/scale research tables/charts Journal Article
Publicado: BMJ Publishing Group Jul2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178602222&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 178602222
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        20479956
        FD0Y
      jtl: European Journal of Hospital Pharmacy
      issn: 20479956
      maglogo: N
    pubinfo:
      dt: Jul2024
      vid: 31
      iid: 4
      pid: 8280
      pub: BMJ Publishing Group
    artinfo:
      ui:
        178602222
        178602222
        178602222
        10.1136/ejhpharm-2022-003545
        178602222
      ppf: 301
      ppct: 9
      formats:
      tig:
        atl: Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.
      aug:
        au:
          Larcombe, Rebecca
          Coulthard, Kingsley
          Eaton, Vaughn
          Tai, Andrew
          Reuter, Stephanie
          Ward, Michael
        affil: University of South Australia, Adelaide, South Australia, Australia
      sug:
        subj:
          Tobramycin Therapeutic Use
          Prescriptions, Drug
          Drug Monitoring
          Prescribing Patterns
          Cystic Fibrosis Drug Therapy
          Cystic Fibrosis Epidemiology
          Human
          United States
          Canada
          United Kingdom
          Ireland
          Australia
          New Zealand
          Surveys
          Thematic Analysis
      ab: Objectives Sophisticated scientific methods have facilitated dose individualisation with substantial advancements in therapeutic drug monitoring (TDM) practice. It is unclear whether these methods have translated to the clinical setting. This study aimed to determine current TDM practice for tobramycin monitoring in cystic fibrosis (CF) centres in the USA and Canada, UK and Ireland, and Australia and New Zealand due to a high prevalence of CF. Methods A web-based survey was developed and circulated via CF specialist groups within the targeted geographical regions. Themes included centre demographics, tobramycin usage, dosing and infusion practices, TDM practices, and blood sampling methods. Results In total 77 responses were received from 75 different CF centres over the 3-month evaluation period (October 2019-January 2020). Respondents were from the USA and Canada (60%), Australia and New Zealand (25%), and the UK and Ireland (15%). Tobramycin was used in 97% of sites, with an international variation in practice across all survey aspects including dosing and infusion practice. TDM-based dose adjustment in the UK and Ireland was most commonly based only on trough sample collection for avoidance of toxicity, where use of computer programs for targeting both efficacy and toxicity endpoints were most common in Australia and New Zealand. The underlying pharmacokinetic basis of that program was not known by 33% of sites who utilised a computer program for tobramycin dose individualisation. Conclusion There remains substantial heterogeneity in tobramycin management worldwide. Despite two decades of research into TDM of tobramycin, there has been a slow uptake of new technologies and evolution of practice. An improved understanding of TDM processes is required for translation of evidence-based research into clinical practice. International guidelines require updating due to the advances in research to support confidence in the changes in clinical practice.
      pubtype: Academic Journal
      doctype:
        questionnaire/scale
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N